✦ LIBER ✦

PEG IFN-α-2b: promising efficacy and tolerability in Ph+ CML

Book ID: 120865322
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2001
Weight: 136 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200113080-00020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

548 Efficacy of PEG-interferon α-2B (PEG

548 Efficacy of PEG-interferon α-2B (PEG-IFN) plus ribavirin in responder-relapsers to a previous course of interferon α plus ribavirin

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 104 KB

Efficacy, safety, and tolerability in pa

Efficacy, safety, and tolerability in patients switched to PEG (40 kDa) IFN α-2a (PEGASYS®) after discontinuation from interferon alfa-2b plus ribavirin (REBETRON™) combination therapy for chronic hepatitis C

✍ Perrillo, Robert P.; Rothstein, Kenneth D.; Alam, Imtiaz; Thuluvath, Paul J.; Pa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 180 KB

78 The HCV NS3 protease inhibitor SCH 50

78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysis

✍ S. Zeuzem; C. Sarrazin; F. Wagner; R. Rouzier; N. Forestier; S. Gupta; M. Hussai 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Efficacy, quality of life, safety, and t

Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN α-2a (PEGASYS®) or standard interferon Alfa-2b/ribavirin (REBETRON™) combination therapy

✍ Kenneth D. Rothstein; Robert P. Perrillo; Joanne Imperial; Imtiaz Alam; Melissa 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 366 KB

Pegylated interferon alpha-2b (Peg-IFN α

Pegylated interferon alpha-2b (Peg-IFN α-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN α-2b plus ribavirin

✍ T. Oze; N. Hiramatsu; T. Yakushijin; M. Kurokawa; T. Igura; K. Mochizuki; K. Ima 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 175 KB

PEG-IFN-α-2b therapy in BCR-ABL–negative

PEG-IFN-α-2b therapy in BCR-ABL–negative myeloproliferative disorders : Final Result of a Phase 2 Study

✍ Elias Jabbour; Hagop Kantarjian; Jorge Cortes; Deborah Thomas; Guillermo Garcia- 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) has shown significant activity in the treatment of BCR‐ABL–negative myeloproliferative disorders (MPDs), particularly essential thrombocythemia (ET) and polycythemia vera (PV). PEG‐IFN‐α‐2b is a pegylated IFN‐α‐2b with a significant advantage ove